Abstract: A method and system for providing vision correction to a patient is disclosed. The method and system employ a vision care POD to engage and provide vision diagnostics and correction options to a patient. More specifically, method and system may include educating the population of a geographic area through sources that target particular identified groups in need of vision correction; providing an eye examination to patients using a vision care POD to generate a personalized vision correction ID card; providing one or more vision correction solution(s) to the patient; supplying the patient with the one or more vision correction solution(s) and the corresponding training for the solution(s); and providing ongoing care and support to the patient.

Abstract: A method and system for providing vision correction to a patient is disclosed. The method and system employ a vision care POD to engage and provide vision diagnostics and correction options to a patient. More specifically, method and system may include educating the population of a geographic area through sources that target particular identified groups in need of vision correction; providing an eye examination to patients using a vision care POD to generate a personalized vision correction ID card; providing one or more vision correction solution(s) to the patient; supplying the patient with the one or more vision correction solution(s) and the corresponding training for the solution(s); and providing ongoing care and support to the patient.

Abstract: Methods for preferentially delivering an active agent intracellularly to a reservoir cell that is infected with or susceptible to infection with an infectious agent, such as HIV. The active agent is part of a lipid-active agent complex that has a targeting ligand, such as a CTL/CTLD receptor-specific anchor, on its outer surface. Targeting systems are also disclosed. Such targeting systems are comprised of lipid-active agent complexes that contain targeting ligands, such as fucose and polyfucose derivatives, on their outer surfaces. The active agents include plant lectins, such as Con-A and MHL, and other drugs. Such methods and targeting systems may be used in the treatment of HIV and other infectious and non-infectious diseases.

Abstract: A method of preferentially delivering an active agent to an immune cell, such as a myeloid progenitor cell, a dendritic cell, a monocyte, a macrophage or a T-lymphocyte, or other cell type restricted to a functional organ system or an anatomic entity, of a mammalian subject by administering a lipid-drug complex to the subject. The lipid-drug complex is comprised of an active agent, such as a drug, and an outer surface with a targeting ligand that binds a marker on the surface of the immune cell or other cell type that is infected with or susceptible to infection with an infectious agent. The other cell type that is infected with or suspectible to infection with an infectious agent may belong to a malignant tumor or a part of the immune system contributing to the development, maintenance, or exacerbation of an autoimmune disease or chronic inflammatory disease.